Share on StockTwits

The Medicines Company (NASDAQ:MDCO) has received a consensus rating of “Hold” from the nine analysts that are presently covering the company, AR Network reports. Seven analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $33.00.

MDCO has been the subject of a number of recent research reports. Analysts at Zacks reiterated a “neutral” rating on shares of The Medicines Company in a research note on Friday, May 30th. They now have a $29.00 price target on the stock. Finally, analysts at Leerink Swann downgraded shares of The Medicines Company from an “outperform” rating to a “market perform” rating in a research note on Thursday, April 17th. They now have a $27.00 price target on the stock, down previously from $30.00.

Shares of The Medicines Company (NASDAQ:MDCO) opened at 28.03 on Friday. The Medicines Company has a 52-week low of $23.53 and a 52-week high of $41.28. The stock has a 50-day moving average of $27.11 and a 200-day moving average of $31.06. The company has a market cap of $1.798 billion and a P/E ratio of 83.42.

The Medicines Company (NASDAQ:MDCO) last issued its quarterly earnings data on Wednesday, April 23rd. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by $0.01. The company had revenue of $177.20 million for the quarter, compared to the consensus estimate of $175.60 million. During the same quarter in the previous year, the company posted ($0.21) earnings per share. The company’s revenue for the quarter was up 13.7% on a year-over-year basis. On average, analysts predict that The Medicines Company will post $-0.16 earnings per share for the current fiscal year.

The Medicines Company, is a pharmaceutical company focused on the treatment of critical care patients through the delivery of medicines to the global hospital marketplace.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.